Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial
Authors:
Open Access
- 25 November 2023
- journal article
- letter
- Published by Elsevier in Kidney International
- Vol. 105 (2) , 381-388
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The Gut-Renal Connection in IgA NephropathySeminars in Nephrology, 2018
- Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy PatientsKidney and Blood Pressure Research, 2018
- Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA NephropathyJAMA, 2017
- New insights into the pathogenesis of IgA nephropathyPediatric Nephrology, 2017
- Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trialThe Lancet, 2017
- Urinary Soluble CD163 in Active Renal VasculitisJournal of the American Society of Nephrology, 2016
- Primary IgA Nephropathy: New Insights Into PathogenesisSeminars in Nephrology, 2011
- Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitisRegulatory Peptides, 2008
- The Role of Secretory IgA and Complement in IgA NephropathySeminars in Nephrology, 2008
- T-cell homing receptor expression in IgA nephropathyNephrology Dialysis Transplantation, 2007